Some Yahooer CMED comments....
Subject: 4Q and Yearly Earnings Date: 8/23/99 6:18 PM
Author: JohnFMoore Number: of 497
Look very good:
4Q Results:
1).NET INCOME:
69% increase in net income. 32% increase in sales.
"Net income in the fourth quarter: increased to $2.6 million compared to $1.6 million in the fourth quarter last year, an increase of 69% on sales of $19.0 million compared to $14.4 million in the fourth quarter of the prior year, an increase of 32%. "
2). EARNINGS PER SHARE: 75% increase.
"Earnings per share: increased to 21 cents per share compared to 12 cents in the fourth quarter of the prior year."
1999 YEAR RESULTS:
1). NET INCOME:
75% increase in net income. 38% increase in sales.
"Net income for the year increased to $7.9 million compared to $4.5 million for fiscal 1998, an increase of 75%, on sales of $65.3 million compared to sales of $47.3 million in the prior year, an increase of 38%. Earnings per share rose to 63 cents per share compared to 37 cents in the prior year on a diluted basis."
=============
Subject: Re: 4Q and Yearly Earnings Date: 8/23/99 10:24 PM
Author: TGreen5000 Number: of 497
They were also added to the list of Fortune's top 100 fastest growing companies, at 59th.
Issue to be dated September 6th, 1999.
Up and up....
====================
Conference number already available
by: fundotech 1958 of 2037
Had bad data, the conference number is
already working. Some of the highlights
I remember:
-Margins were up again to over 39% amazingly
-General expenses as percentage of revenues
were down significantly just as amazingly
-$23 million in cash, no debt
-Gen Probe manufacturing revenues to hit
stride in 1st half of 2000
-Fresh Aire received an approval (UL) FDA
was waiting for and FDA approval is close.
BioMed will market this vigorously. The CEO
seemed to be relieved that someone actually
asked about this and basically said that
neither the analysts or CMED has priced in
any benefits from Fresh Aire and so any
benefit will be a freebie.
-5-6 DNA projects still
-R&D is down, they're working on the Hitachi deal
-Creos main customers are the same as CMED,
in particular Hitachi so same sales force should
be able to pick this up, 25 of 27 employees
retained, it was cheap because of the
financial condition of the company
-Employees have gone from 400 to 575 or so in
the last year.
-International sales are growing and this means
less money spent on taxes apparently.
And I certainly might have missed something.
The analysts seemed a bit more muted in their
praise at this call than in the past in my humble
opinion, possibly because the stock has already
priced much of this in already, but in general,
a very positive quarter.
Let's see how this one pans out.
GLTA.
:) Dan
==================
Genprobe
by: nothingbutthefacts 1964 of 2037
A substantial number of the new institutions in the stock have become increasingly intrigued by CMED's ability to get large, substantially untouted contracts such as Genprobe and Hitachi.
Atanasoff responded to one institutions question on Genprobe on the call by indicating that shipment rates of 5-10 units monthly of Tigris should commence in the second fiscal half of the year. My recollection is that at 10 units a month, CMED generates another $1.5 million a month in revenues.
Additionally the prospects for Hitachi's manufacturing probably starts to show up mid year fiscal 2001, which has been substantially downplayed publicly, but not by the analysts covering the stock. Add the prospects for this contract to Genprobe and CMED's quarterly revenues could grow by about 50% on solely these two developments, over time.
CMED's Hitachi win was incredibly significant, partially due to the behind the scenes belief that Hitachi's MRI division had never outsourced a major R&D and potentially major manufacturing project to anyone outside of Japan. Still wondering if CMED is world class?
Inside the numbers, shows Atanasoff's resolve not to spend on G&A unnecessarily. Although gross margin, operating income and all other measurements screamed about the robustness of the numbers, G&A hardly budged.
Although Creos was downplayed on the call, CMED will extract the most for the least, as always. Atanasoff did say it would leverage ERBTEC's capabilities in the X-ray industry dramatically due to its technical expertise.
DNA probe projects (still undisclosed) continue to be having the shark feeding frenzy below the surface. Once again you have to dig deeper.
|
